Deberdt R
J Int Med Res. 1981;9(1):69-73. doi: 10.1177/030006058100900112.
The efficacy of ketazolam (Solatran) in alleviating the symptoms of short-term reactive or neurotic anxiety in thirty-three patients was examined using a single 30 mg night-time dose in an open study. Patients were to receive treatment for up to 1 month and thereafter as necessary for several months. At the follow-up visits, at the end of the first, second and fourth weeks and then at the end of therapy if continued, the clinical condition was assessed by the Hamilton Anxiety Rating Scale and physician's and patients' subjective global assessments. A highly significant improvement was observed after a week's treatment in both somatic and psychic aspects of anxiety. A favourable response as measured by the two subjective assessments was observed in more than 80% of the patients by the third visit. There were two reports of morning tiredness, both dose-related, but no other adverse effects. Only four patients derived no benefit from the treatment.
在一项开放性研究中，使用单次夜间30毫克剂量对33例患者进行了氯氮卓（索拉坦）缓解短期反应性或神经性焦虑症状疗效的检查。患者接受治疗最长可达1个月，之后根据需要持续数月。在随访时，即在第一、第二和第四周结束时，以及如果继续治疗则在治疗结束时，通过汉密尔顿焦虑评定量表以及医生和患者的主观整体评估来评估临床状况。治疗一周后，焦虑的躯体和精神方面均观察到高度显著的改善。到第三次就诊时，超过80%的患者在两项主观评估中显示出良好反应。有两例晨起疲倦的报告，均与剂量相关，但无其他不良反应。只有4例患者未从治疗中获益。
